Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307200 | 1.00 | ATM (0.39) | ATMHSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL16857528 | 1.00 | ATM (0.39) | ATMHSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL6897583 | 0.84 | PREP (0.38) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL6897589 | 0.84 | PREP (0.38) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL4843577 | 0.78 | ATM (0.36) | ATMHSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL14209894 | 0.78 | ATM (0.39) | ATMHSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL12203690 | 0.78 | ATM (0.39) | ATMHSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL27538723 | 0.78 | ATM (0.39) | ATMHSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL2277430 | 0.78 | NR1H2 (0.44) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL7914485 | 0.77 | NR1H2 (0.42) | ATMHSD17B10NR1H2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | claimed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | claimed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | claimed |
| EP-1819693-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006057868-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | claimed |
| US-9278996-B2 | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same | CELLTRION, INC. (KR) | 2016-03-08 | — | — | US | disclosed |
| US-9278996-B2 | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same | CELLTRION, INC. (KR) | 2016-03-08 | — | — | US | disclosed |
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | CELLTRION, INC. (KR) | 2015-08-13 | — | — | US | disclosed |
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | CELLTRION, INC. (KR) | 2015-08-13 | — | — | US | disclosed |
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2003-12-18 | — | — | US | disclosed |
| US-6605608-B1 | Such as n-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t -butoxycarbonylthiazolidin-4-ylcarbonylamino)propan-a mide; n-type calcium channel inhibitors | ONO PHARMACEUTICAL CO., LTD (JP) | 2003-08-12 | — | — | US | disclosed |
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| EP-1090912-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-04-11 | — | — | EP | disclosed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | disclosed |
| EP-0986384-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998050029-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225455-A1 | DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING THE SAME AND ANTICANCER DRUG COMPOSITION CONTAINING THE SAME | DAD1, DDOST, SCD5 | ATM 3455/4885HSD17B10 127/4885NR1H2 258/4885 |
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | ATM 3348/4885HSD17B10 1348/4885NR1H2 2516/4885 |
| US-20030013725-A1 | Amino acid derivatives | CACNA1B, SCN1A, SCN2A | ATM 3517/4885HSD17B10 1544/4885NR1H2 550/4885 |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1S, CACNA1B | ATM 2618/4885HSD17B10 4741/4885NR1H2 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.